Table 2:

Efficacy and Safety Outcomes

Outcome	Alteplase (n=429)	Control (n=414)	Odds ratios (95% CI) *	p-value
Primary Efficacy Outcome
Favourable Outcome (mRS 0–1) at 90 days – no. (%) †	199 (47%)	160 (39%)	1.49 (1.10–2.03)	0.011
Secondary Efficacy Outcomes
mRS score at 90 days ‡			1.38 (1.05–1.80)	0.019
Independent Outcome (mRS 0–2) at 90 days – no. (%) †	273 (65%)	239 (58)	1.50 (1.06–2.12)	0.022
Safety Outcomes
Death at 90 days – no. (%) †	27 (6%)	14 (3%)	2.06 (1.03–4.09)	0.040
Death at 7 days – no. (%)	10 (2%)	4 (1%)	2.54 (0.78–8.32)	0.19
Severe disability or death (MRS 4–6) at 90 days – no. (%) †	90 (21%)	102 (25%)	0.76 (0.52–1.11)	0.15
Dependence or death (MRS 3–6) at 90 days – no. (%) †	147 (35%)	170 (42%)	0.67 (0.47–0.94)	0.022
Symptomatic intracerebral haemorrhage – no. (%)	11 (3%)	2 (<1%)	5.58 (1.22–25.50)	0.024
Parenchymal haemorrhage type 2 (PH-2) – no. (%) ‡	11 (3%)	3 (1%)	3.51 (0.98–12.60)	0.068

mRS denotes modified Rankin scale

^*Odds ratios were adjusted for age and symptom severity at baseline.

^†Numbers are given for patients with available data on the primary efficacy endpoint; mRS at day 90 was missing for 9 patients in the alteplase and 5 in the control group; missing primary outcome values were replaced using multiple imputation.

^‡Radiological assessment of parenchymal haemorrhage type 2 (PH-2) was available for 320 patients in the alteplase and 307 in the control group